Average Award
The award typically entails up to $600,000 over 2 years with dedicated support for milestone-driven projects from a team of industry veterans with capabilities that include medicinal chemistry, pharmacology & toxicology, and business development. The expertise of each team is tailored to the specific needs of the project during the two-year award period.
DEADLINES
Letter of Intent: (Extended) June 9, 2025, 5:00 PM EDT
Full Proposal: August 18, 2025, 5:00 PM EDT
Award decisions are anticipated by March 2026.
Drug Targets
The 2026 ADDF-Harrington Scholar RFP places high priority on targets related to emerging therapeutic areas for dementia, particularly:
ADDF functions like a venture fund: when supporting academia, they expect a share in any commercial returns; with biotech, they may take equity, royalties, or convertible notes
Demonstrate a clear commercial path—composition-of-matter IP or novel therapeutic modalities are prioritized
The Drug Development RFP targets IND-enabling studies and early-phase clinical trials (Phase 0–2a), especially for drugs with novel mechanisms—excluding traditional anti-amyloid or cholinesterase inhibitors
Applicants must justify:
The novelty of the mechanism
Genetic or human biology support
Biomarker linkages and pathway to demonstrate target engagement
Multi-year grants (up to max ~$5M) require IND-enabling studies (toxicology, GMP production) or early human trials with measurable biomarker and clinical endpoints
Include well-structured milestones, timelines, and demonstrate ability to recruit subjects and engage biostatisticians early
ADDF looks for strong teams combining scientific, clinical, regulatory, and business expertise; partnerships with CROs are encouraged
For biotechs, the business review board evaluates management, IP, and commercial viability
Only direct costs are allowed (e.g., personnel, consumables, small equipment ≤ $2.5K); no indirect costs
Grant amounts vary by stage; up to $5M is possible, but budget must align with milestones
Process includes LOI → invited full proposal → iterative review by scientific and business panels
Therapeutics applicants may resubmit up to two times addressing critiques point-by-point
ADDF invests in non-financial support: expert guidance on preclinical/clinical strategy, regulatory affairs, partnership-building
They also fund diagnostics accelerators, like the Biomarker Observatory, supporting blood, neuroimaging, and digital biomarker development
✅ Summary Table
Predictor | What to Do |
---|---|
Business alignment | Showcase IP/commercial path and readiness for venture-philanthropy model |
Scientific novelty and rigor | Propose a biomarker-supported, non-amyloid mechanism with strong evidence |
Milestone-based feasibility | Include clear, measurable research milestones and timelines |
Collaborative team structure | Combine scientific, clinical, regulatory, and business expertise |
Direct-cost budgeting | Build precise budgets (no indirects or travel), aligned with milestones |
Iterative submission planning | Prepare LOI, full proposal, and be ready to resubmit based on ADDF feedback |
Non-financial support utilization | Leverage mentorship, networking, and diagnostic platform resources |
🚀 Pro Tips to Boost Your Proposal
Start with LOI clarity: define the novel mechanism, target, biomarkers, and scale.
Line up partnerships: include CROs or biotech collaborators early.
Detail your clinical/IND plan: incorporate biostatistics, subject recruitment, regulatory path.
Budget for milestones: base funding tranches on deliverables.
Engage with ADDF: reach out if your project fits the RFP or needs feedback.
Plan resubmissions: prepare to refine based on board input.
Eligible Countries:
Sponsor Institute/Organizations: Alzheimer's Drug Discovery Foundation
Sponsor Type: Corporate/Non-Profit
Address: 57 West 57th Street, Suite 904 New York, NY 10019 info@alzdiscovery.org 212.901.8000
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Aug 18, 2025
$600,000
Affiliation: Alzheimer's Drug Discovery Foundation
Address: 57 West 57th Street, Suite 904 New York, NY 10019 info@alzdiscovery.org 212.901.8000
Website URL: https://www.alzdiscovery.org/research-and-grants/funding-opportunities/harrington
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.